Statin Pharmacology in Oncology

Statins, originally developed as cholesterol-lowering agents, inhibit the enzyme HMG-CoA reductase and thus the mevalonate pathway. Beyond cardiovascular benefits, accumulating evidence positions statins as modulators of tumour biology through pleiotropic effects on cell proliferation, apoptosis, metastasis and the tumour microenvironment. By depleting essential isoprenoids, statins disrupt prenylation of small GTPases such as Rho, Ras and Rab, impeding key signalling cascades including PI3K–Akt, MAPK–ERK and integrin-FAK pathways. These molecular interventions lead to cell cycle arrest, intrinsic apoptotic activation and reduced invasive potential across a spectrum of malignancies. Furthermore, statins influence metabolic reprogramming in cancer cells and can synergise with targeted therapies to unmask collateral vulnerabilities, particularly in drug-resistant phenotypes. The global availability, safety profile and established pharmacokinetics of statins underscore their promise for repurposing as adjuvant agents in oncology.

Research from Nature Portfolio

Recent studies have revealed novel collateral vulnerabilities to statin therapy in treatment-resistant melanoma. Epigenetic downregulation of a mitochondrial regulator creates a dependency on prenylated proteins, rendering persistent tumours sensitive to HMG-CoA reductase inhibition. In this context, statin treatment curtailed tumour growth by reducing prenylation of key small GTPases, inhibiting integrin localisation and downstream survival signalling. Foundational investigations have further characterised statin-induced intrinsic apoptosis across diverse tumour cell lines. By depleting geranylgeranyl pyrophosphate and farnesyl pyrophosphate, statins triggered mitochondrial cytochrome c release and activated caspase-dependent cell death, an effect rescued by isoprenoid supplementation. These insights elucidate core mechanisms through which statins exert anticancer activity and support their integration into precision-medicine frameworks.

Statin Pharmacology in Oncology publication trend

The graph below shows the total number of articles in statin pharmacology in oncology across all publications each year (not limited to Nature Index journals).

Technical terms

HMG-CoA reductase: Enzyme catalysing the rate-limiting step of cholesterol synthesis.

Mevalonate pathway: Biosynthetic cascade producing isoprenoid intermediates essential for protein prenylation.

Prenylation: Lipid modification of proteins that facilitates membrane localisation and signalling activity.

PGC1α: Transcriptional coactivator regulating mitochondrial biogenesis and oxidative metabolism.

SREBP2: Sterol regulatory element-binding protein that controls genes involved in cholesterol homeostasis.

References

1. Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas. Nature Communications (2023).
2. Combined metformin and simvastatin therapy inhibits SREBP2 maturation and alters energy metabolism in glioma. Cell Death & Disease (2024).
3. Glycolysis-cholesterol metabolic axis in immuno-oncology microenvironment: emerging role in immune cells and immunosuppressive signaling. Cell & Bioscience (2023).
4. Statins: a repurposed drug to fight cancer. Journal of Experimental & Clinical Cancer Research (2021).
5. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget (2015).
6. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells. Scientific Reports (2017).